ANG Lifesciences India MD, chairman, board of directors and AGM
BSE: 540694Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹34.15.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹43 Cr3,715th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 May 2026
- 0.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 Aug 2026
- −22.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- −6.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 May 2026
- 1.47
- Volume, BSEVolume. Shares traded on the last trading day.
- 3,136
ANG Lifesciences India board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- Managing directorRajesh Gupta
6 directors3 independent2 executive1 non-executive
- Rajesh Gupta · Managing directorExecutive · joined Jun 2006 · reappointed Sep 2024 · 223 months as independent · 1 listed board · 1 committee seat
- Saruchi GuptaExecutive · joined Apr 2011 · reappointed Sep 2024 · 165 months as independent · 1 listed board · 1 committee seat
- Rohit MittalNon-executive · joined Oct 2023 · reappointed Sep 2024 · 27 months as independent · 1 listed board · 1 committee seat, 1 as chair
- Harvinder Singh DhamiIndependent · joined May 2024 · reappointed Sep 2024 · 19 months as independent · 2 listed boards · 2 as independent
- Sukhpal SinghIndependent · joined May 2016 · reappointed Nov 2021 · 116 months as independent · 1 listed board · 1 as independent · 1 committee seat, 1 as chair
- ChetnaIndependent · joined Oct 2021 · reappointed Sep 2026 · 51 months as independent · 5 listed boards · 5 as independent · 4 committee seats, 4 as chair
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 7 Sep 20265 of 6 present3 independent · 23 days in between
- 14 Aug 20265 of 6 present3 independent · 75 days in between
- 30 May 20266 of 6 present3 independent
Audit Committee
Chair Sukhpal Singh
Chetna, Saruchi Gupta
- 7 Sep 20263 of 3 present2 independent · 23 days in between
- 14 Aug 20263 of 3 present2 independent · 75 days in between
- 30 May 20263 of 3 present2 independent
Nomination and remuneration committee
Chair Sukhpal Singh
Harvinder Singh Dhami, Rohit Mittal
- 7 Sep 20263 of 3 present2 independent
Stakeholders Relationship Committee
Chair Rohit Mittal
Rajesh Gupta, Chetna
- 7 Sep 20262 of 3 present1 independent
Corporate Social Responsibility Committee
Chair Saruchi Gupta
Sukhpal Singh, Rohit Mittal
No meeting listed in the filing.
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- M/s Khurana Sharma & CompanyPeer-review certificate valid to Feb 2027
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
ANG Lifesciences India AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.ANG Lifesciences India dividend history
Annual general meeting, 30 Sep 2026
5,851 shareholders on the register on 23 Sep 2026; present: 2 promoters and 35 others; votes counted by Anil Negi / Anil Negi & Company.The company's voting result (opens in a new tab)
- To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the financial year ended 31st March, 2026 and the reports of the Board of Directors and Auditors thereon.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 2.35% · promoters 0.00% · institutions 0.00% · other public 7.99%
- To receive, consider and adopt the Audited Consolidated Financial Statements of the company for the financial year ended 31st March, 2026 together with the reports of Auditors thereon.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 2.35% · promoters 0.00% · institutions 0.00% · other public 7.99%
- To appoint a director in place of Mr. Rohit Mittal (DIN: 10349180), who retires by rotation and being eligible, offers him-self for re-appointment.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 2.35% · promoters 0.00% · institutions 0.00% · other public 7.99%
- Ratification of the Cost Auditor Remuneration for the financial year 2026-27Ordinary99.78% for0.22% against
Against: promoters 0.00% · institutions 0.00% · other public 0.22%
Turnout: all 2.35% · promoters 0.00% · institutions 0.00% · other public 7.99%
- To re-appoint Ms. Chetna (DIN: 08981045) as an Independent Director of the company.Special99.78% for0.22% against
Against: promoters 0.00% · institutions 0.00% · other public 0.22%
Turnout: all 2.35% · promoters 0.00% · institutions 0.00% · other public 7.99%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- No
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.